Vistagen Therapeutics, Inc.
Number not stated
SEC filingAnnounced
Vistagen Therapeutics, Inc. discloses a restructuring plan in an SEC filing
- Industry
- Biotech
- Filed with the SEC
- October 30, 2026
- Share of workforce
- 31%
- Whose workers
- Scope not stated
- In the report for
- October 31, 2026
What happened
Vistagen Therapeutics, Inc. disclosed a restructuring plan in an SEC filing without stating how many jobs it affects. The filing puts the reduction at about 31% of its workforce.
Sources
SEC EDGAR · SEC filing · Oct 30, 2026
(the “ Company ”) implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for U.S. registration-directed Phase 3 development of fasedienol, its lead clinical-stage product candidate for treatment of social anxiety disorder, as well as potential future development of its lead Phase 2 product candidates, itruvone for major depressive disorder and refisolone for menopausal hot flashes.
Read the source